Genmab A/S (CPH:GMAB)
1,847.00
-22.00 (-1.18%)
Jul 20, 2026, 4:59 PM CET
Genmab Employees
Genmab had 3,088 employees as of March 31, 2026. The number of employees increased by 450 or 17.06% compared to the same quarter last year.
Employees
3,088
Change
450
Growth
17.06%
Revenue / Employee
8.19M DKK
Profits / Employee
1.72M DKK
Market Cap
114.74B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 3,088 | 450 | 17.06% |
| Dec 31, 2025 | 2,973 | 339 | 12.87% |
| Sep 30, 2025 | 2,681 | 46 | 1.75% |
| Jun 30, 2025 | 2,639 | 113 | 4.47% |
| Mar 31, 2025 | 2,638 | 352 | 15.40% |
| Dec 31, 2024 | 2,634 | 430 | 19.51% |
| Sep 30, 2024 | 2,635 | 503 | 23.59% |
| Jun 30, 2024 | 2,526 | 511 | 25.36% |
| Mar 31, 2024 | 2,286 | 440 | 23.84% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Sep 30, 2023 | 2,132 | 572 | 36.67% |
| Jun 30, 2023 | 2,015 | 570 | 39.45% |
| Mar 31, 2023 | 1,846 | 537 | 41.02% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Sep 30, 2022 | 1,560 | 424 | 37.32% |
| Jun 30, 2022 | 1,445 | 416 | 40.43% |
| Mar 31, 2022 | 1,309 | 438 | 50.29% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novo Nordisk | 67,900 |
| Demant | 26,704 |
| Coloplast | 17,083 |
| GN Store Nord | 7,736 |
| Ambu A/S | 5,200 |
| H. Lundbeck | 5,000 |
| Embla Medical | 4,500 |
| ALK-Abelló | 2,759 |
Genmab News
- 5 days ago - Genmab Reports Q2 Worldwide Net Trade Sales Of DARZALEX - Finanz Nachrichten
- 5 days ago - Genmab reports Q2 net sales of Darzalex $4.207B - TheFly
- 5 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026 - GlobeNewsWire
- 5 days ago - Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2026 - Wallstreet:Online
- 13 days ago - Genmab Wins EU Nod For TEPKINLY Combo In Follicular Lymphoma - Nasdaq
- 14 days ago - Genmab says EC grants marketing authorization for Tepkinly combo - TheFly
- 14 days ago - Genmab A/S: Genmab Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - Finanz Nachrichten
- 14 days ago - Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire